Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
November 2024
in “
SKIN The Journal of Cutaneous Medicine
”
Studysummary This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on skin.dermsquared.com →